TY - JOUR
T1 - Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab
AU - Noshela Ghazanfar, M
AU - Thomsen, S F
PY - 2017/11
Y1 - 2017/11
N2 - Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.
AB - Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.
U2 - 10.23822/EurAnnACI.1764-1489.08
DO - 10.23822/EurAnnACI.1764-1489.08
M3 - Journal article
C2 - 29249138
VL - 49
SP - 284
EP - 285
JO - European Annals of Allergy and Clinical Immunology
JF - European Annals of Allergy and Clinical Immunology
SN - 1764-1489
IS - 6
ER -